The drug, used in conjunction with other antiretroviral medications, may be used to both prevent and treat HIV infections.
In 2016, Gilead Sciences posted U.S. sales of nearly $2.4 billion for Truvada. The drug’s list price — about $1,500 per month — has hindered patient access to the medication, according to Regulatory Focus.
Paul Volberding, director of the AIDS Research Institute at the UC San Francisco, believes Teva’s generic version may improve access and lower costs of the HIV treatment, according to the report.
Teva did not say how much its generic version will cost or when it will hit the market.
More articles on supply chain:
Bristol-Myers susceptible to acquisition following failed cancer trial, investors say
FDA approves Qiagen’s TB blood test: 3 things to know
7% of cancer patients say pharma prices drugs fairly: 5 survey findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
